Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

61 results about "Antidote" patented technology

An antidote is a substance that can counteract a form of poisoning. The term ultimately derives from the Greek term φάρμακον ἀντίδοτον (pharmakon) antidoton, "(medicine) given as a remedy". Antidotes for anticoagulants are sometimes referred to as reversal agents.

Application of inhibitor JSH-23 in preparation of medicine for preventing and / or treating ovarian toxicity caused by combined exposure of environmental toxins

The invention belongs to the technical field of cytotoxicity intervention, and particularly relates to application of an inhibitor JSH-23 in preparation of a medicine for preventing and / or treating ovarian toxicity caused by environmental toxin combined exposure. Aiming at the condition that MC-LR and NaNON combined exposure can activate NF-kappa B to induce KK-1 cell nitrification stress and cause mouse ovarian dysfunction, JSH-23 is selected as an intervention agent, and it is found that after KK-1 cells are pretreated by JSH-23, NF-kappa B nuclear translocation induced by the KK-1 cells due to MC-LR and NaNON combined exposure is remarkably inhibited, iNOS protein rising induced by toxin combined exposure is remarkably reduced, and NF-kappa B nuclear translocation induced by the KK-1 cells due to NF-kappa B combined exposure is remarkably inhibited. The increase of the levels of ONOO and 3-NT of nitration stress markers is effectively relieved, which indicates that JSH-23 can participate in the nitration stress of KK-1 cells caused by combined exposure of MC-LR and NaNO2 by inhibiting NF-kappa B activation, and a foundation is laid for screening antidotes after exposure of environmental toxins.
Owner:ZHENGZHOU UNIV

A macromolecular heavy metal complexing agent containing 8-hydroxyquinoline and amido phosphate structure and a preparation method thereof

The present application relates to a kind of macromolecular heavy metal complexing agent containing 8-hydroxyquinoline and amido phosphate structure and its preparation method, the present application also relates to a kind of heavy metal antidote, and the use of the macromolecular heavy metal complexing agent of the present application in preparing drug for treating heavy metal poisoning.The macromolecular complexing agent of the present application has excellent binding capacity with cadmium, lead, mercury and other heavy metal ions, and is high in safety, has excellent and long-acting heavy metal protection effect.The preparation method of the present application can mass, simply and efficiently prepare the macromolecular complexing agent of the present application, and preparation process is simple, high in yield, raw material is cheap and easy to obtain, reaction condition is mild.
Owner:TSINGHUA UNIVERSITY

Paraquat antidote

The invention relates to a paraquat antidote, and belongs to the technical field of paraquat detoxification. The invention discloses an application of choline materials and glucosamine in preparation of a paraquat antidote. According to the application, the choline material can competitively inhibit the activity of paraquat small intestine transporter and effectively inhibit the absorption of paraquat in small intestines, so that the concentration of paraquat in blood is reduced, the toxicity of paraquat is reduced, and the survival rate of acute poisoning rats is increased from 0% to 50%; according to the application, the glucosamine up-regulates the expression of P-glycoprotein in the lung of the rat, promotes the paraquat to be pumped out of lung cells, reduces the concentration of paraquat in the lung, and improves the survival rate of the acute poisoning rat from 0% to 40%; in the application, choline materials and glucosamine are combined for use, so that the survival rate of paraquat poisoning rats can be remarkably increased from 0% to 80% or above, and the medicine is expected to be applied to detoxification of paraquat poisoning of human bodies.
Owner:SOUTHWEST UNIV

Polyheterocyclic uncharged bisoxime antidotes for organophosphate poisoning and methods for making and using them

In alternative embodiments, provided are polyheterocyclic uncharged bisoxime antidotes, including polyheterocyclic uncharged bisoximes, and methods for treating, preventing or ameliorating excessive acetylcholine stimulation in the brain comprising administering to an individual in need thereof a polyheterocyclic uncharged bisoxime antidote as provided herein. In alternative embodiments, provided are methods for treating, preventing or ameliorating excessive acetylcholine stimulation in the brain; or, treating, ameliorating or protecting (preventing) an organophosphate toxicity or poisoning or toxic exposure, or for treating, ameliorating or protecting (preventing) organophosphate inhibition of an acetylcholinesterase (AChE) comprising administering to an individual in need thereof a polyheterocyclic uncharged bisoxime antidote as provided herein.
Owner:RGT UNIV OF CALIFORNIA

Artificial nucleic acid aptamer and medical application thereof

The invention relates to a nucleic acid aptamer DNA sequence as shown in SEQ ID NO.1 or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the nucleic acid aptamer sequence or the pharmaceutically acceptable salt thereof as an active ingredient. The invention also discloses application of the nucleic acid aptamer sequence or the pharmaceutically acceptable salt thereof in preparation of antidote drugs used as ricin and / or abrus precatorius toxin.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Compositions and methods related to nucleic acid anticoagulants

To provide clinical anticoagulants that are advantageous for use as surgical anticoagulants and are of sufficiently high molecular weight to greatly reduce rapid renal clearance.SOLUTION: The present disclosure provides a single-stranded nucleic acid molecule that includes at least one A-form double-helical structure and at least one crossover region, at least one kissing-loop region, and at least one nucleic acid aptamer having anticoagulant activity. The present disclosure also provides nucleic acid molecules comprising one or more aptamers having anticoagulant activity, as well as corresponding nucleic acid antidotes, for modulation of blood coagulation relating to disease and surgical intervention.SELECTED DRAWING: Figure 1
Owner:NORTH CAROLINA STATE UNIV

The use of β-glucuronidase in the preparation of an antidote for the prevention and / or treatment of zearalenone poisoning, and an antidote for the prevention and / or treatment of zearalenone poisoning.

ActiveCN121606700Breduce exposureClear technical pathOrganic active ingredientsAntinoxious agentsEnzyme Inhibitor AgentGlucuronidase Inhibitor
This invention provides the use of β-glucuronidase in the preparation of an antidote for the prevention and / or treatment of zearalenone poisoning, and an antidote for the prevention and / or treatment of zearalenone poisoning, belonging to the field of feed additives. This invention, for the first time from the perspective of in vivo exposure control in animals, proposes a method to reduce the overall ZEN exposure level by inhibiting the activity of intestinal bacterial β-glucuronidase. The technical path is clear and highly operable. This is achieved through in vivo toxicokinetic parameters (AUC, C...). max Changes in (and / or MRT) objectively reflect a reduction in ZEN exposure levels in vivo, and the technical effects are quantifiable and verifiable. The β-glucuronidase inhibitors used in this invention are widely available, particularly suitable for the field of feed additives, and have promising application prospects.
Owner:INSTITUTE OF ANIMAL SCIENCES OF CHINESE ACADEMY OF AGRICULTURAL SCIENCES

Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same

PendingUS20250186563A1Peptide/protein ingredientsAntinoxious agentsAntidoteFactor Xa Inhibitor
The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
Owner:ALEXION PHARMACEUTICALS INC

Nanodiamonds as delivery platform for oxime antidotes to central nervous system in organophosphate poisoning

Detonation nanodiamond nanocarrier platforms to transport quaternary oxime antidotes into the central nervous system have been developed. The nanodiamond-based AChE reactivators contain an organophosphorus poisoning antidote (e.g., a 4-hydroximinopyridinium moiety) bound to a biocompatible linker covalently attached to the nanodiamonds. These functionalized nanodiamonds successfully cross the layer of Madin-Darby Canine Kidney (MDCK) cells, the epithelial cell surrogate BBB model, and demonstrate a measurable dose-independent in vitro reactivation capacity towards human AChE inhibited by toxic organophosphorus compounds.
Owner:TALLINN UNIVERSITY OF TECHNOLOGY +1

Development of potential antidotes for arsenicals

The present disclosure is concerned with purine diamine compounds for the treatment of conditions associated with BRD4, RIP3K, and / or IL6 signaling dysfunction such as, for example, cancer (e.g., lung cancer, skin cancer, bladder cancer, kidney cancer, liver cancer), arsenicosis, arsenic poisoning, inflammation, skin lesions, dysfunction of systemic organs, and skin blisters. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Owner:THE UAB RESEARCH FOUNDATION INC +2

Use of the compound SCH 23390 for the preparation of a medicament for the treatment of lead poisoning

The application discloses application of a compound SCH23390 in preparation of a medicine for treating lead poisoning, and relates to the technical field of medicines. The application studies the efficiency of the compound SCH23390 in treatment of lead poisoning, first discloses the treatment effect of the compound SCH23390 on lead poisoning, breaks through the limitation of an existing drug target point, directly corrects abnormal nerve signals by inhibiting excessive activation of D1 neurons, avoids side effects of central excessive excitation, and has no significant toxic side effects under a treatment dose. In particular, the compound SCH23390 can significantly relieve specific abnormal behavior phenotypes caused by low-dose lead poisoning, and exhibits better neuroprotective characteristics than traditional chelating agents. The application breaks through the limitation of a single chelating antidote in the traditional field of lead poisoning treatment, and provides a new direction for development of anti-lead toxicity medicines with multiple target points and multiple mechanisms.
Owner:HEFEI UNIV OF TECH

Magnetic bead immobilized snake venom phospholipase A2 as well as preparation method and application thereof

The invention belongs to the technical field of medicine separation, and particularly relates to magnetic bead immobilized snake venom phospholipase A2 as well as a preparation method and application thereof. The preparation method comprises the following steps: carrying out a coupling reaction on ferroferric oxide nanoparticles and (3-aminopropyl)-triethoxysilane in an organic solvent, washing, and drying to obtain aminated magnetic beads; and activating the aminated magnetic beads with glutaraldehyde, incubating with a snake venom phospholipase A2 solution, and reacting to obtain the magnetic bead immobilized snake venom phospholipase A2. The magnetic bead immobilized snake venom phospholipase A2 prepared by the invention can be used for rapidly and accurately fishing the snake venom phospholipase A2 toxin antidote from a mixture system, and has a better application prospect in the field of snake venom antidote research.
Owner:NANCHANG UNIV

High-affinity thrombin aptamers and methods of use

Disclosed are aptamers, aptamer antidotes, and their use in the treatment of thrombosis and other thrombotic conditions.
Owner:AYASS BIOSCIENCE LLC

Phytonadione for parenteral administration

The present invention relates to an aqueous pharmaceutical composition for parenteral administration to a human, comprising a pharmacologically effective amount of a pharmaceutically acceptable vitamin K, a polyethoxylated castor oil as solubilizer, and a citrate buffer at a concentration of 1 to 40 mmol / L, wherein the pH of the composition is between 3.5 and 7.0, to a pharmaceutically acceptable container comprising the composition, and to the composition for use in the treatment or prevention of vitamin K deficiency and / or haemorrhage or for use as an antidote to anticoagulants of the coumarin type as well as to a method for preparing the composition.
Owner:FRESENIUS KABI AUSTRIA GMBH

Application of chlorogenic acid in preparation of medicine for treating glyphosate-induced renal toxicity diseases

The invention relates to the technical field of pharmaceutical biology, aims to solve the problem of lack of specific detoxification drugs for treating glyphosate poisoning clinically, and particularly provides application of chlorogenic acid in preparation of drugs for treating glyphosate-induced renal toxicity diseases. The drug mechanism of the chlorogenic acid is as follows: glyphosate-induced renal toxicity is antagonized through targeted renal injury biomarkers, wherein the renal injury biomarkers comprise TIM-1, TIMP-2, IGFBP7 and LCN2. The invention also provides a preparation for preventing and / or relieving and / or treating glyphosate-induced renal toxicity diseases, wherein the preparation contains chlorogenic acid. The preparation can be a medicine, a pharmaceutical composition, a health care product, a food or an additive. The medicine prepared by the invention can be used for remarkably reducing the expression levels of TIM-1, TIMP-2, IGFBP7 and LCN2 of the GLY-induced renal injury. In addition, oxidative stress (LCN2), cell cycle arrest (TIMP-2 / IGFBP7) and inflammatory reaction (TIM-1) can be synchronously and accurately inhibited, and the curative effect is superior to that of a current single-channel medicine.
Owner:HUBEI UNIV OF SCI & TECH

Application of compound SCH23390 in preparation of medicine for treating lead poisoning

The invention discloses application of a compound SCH23390 in preparation of a medicine for treating lead poisoning, and relates to the technical field of medicines. The invention studies the efficacy of the compound SCH23390 in the treatment of lead poisoning, reveals the treatment effect of the compound SCH23390 on lead poisoning for the first time, breaks through the limitation of existing drug targets, directly corrects abnormal neural signals by inhibiting excessive activation of D1 neurons and avoids the side effect of central hyperexcitation, and has no obvious toxic or side effect under the treatment dosage, especially, the compound SCH23390 can be used for treating lead poisoning. The compound SCH23390 can obviously relieve specific abnormal behavior phenotypes caused by low-dose lead poisoning, and shows the nerve protection characteristic superior to that of a traditional chelating agent. The limitation that the traditional lead poisoning treatment field depends on a single chelating antidote is broken through, and a brand new direction is provided for developing multi-target and multi-mechanism anti-lead-toxicity drugs.
Owner:HEFEI UNIV OF TECH

Nicotinoid antidote as well as preparation method and application thereof

The invention discloses a nicotine substance antidote as well as a preparation method and application thereof, and particularly relates to application of methylene blue or salt thereof in preparation of an antidote for relieving thiamethoxam poisoning. Experiments prove that methylene blue or the salt thereof can effectively control, relieve and treat thiamethoxam poisoning symptoms, has a good detoxification effect and can prevent thiamethoxam poisoning in advance. Therefore, the methylene blue or the salt thereof provided by the invention can be used in the fields of medicines and the like, can effectively reduce death of birds and insect animals caused by thiamethoxam poisoning, stabilizes biologic chain circulation, and ensures the quality and yield of agricultural products.
Owner:ANHUI AGRICULTURAL UNIVERSITY

Compositions for upper respiratory tract administration and methods of administering the same

The present invention discloses a composition for upper respiratory tract administration, which is used for the treatment and protection of fire injuries and contains a cyanide antidote and a metal chelating agent; with the appropriate carrier combination, the composition can be administered to the required individual in the form of a spray, an inhalant or a drop, etc. to prevent or treat the injuries caused by harmful substances at the fire scene.
Owner:ORIGINAL BIOMEDICALS

Preparation and application of skeleton type vomitoxin antidote

The invention discloses preparation and application of a skeleton type vomitoxin antidote, and relates to the technical field of feed processing, and the skeleton type vomitoxin antidote is characterized in that the antidote is prepared from 60-70% of Na2S2O5 and 30-40% of a composite carrier through a hot melt extrusion instrument under the conditions that the sleeve outlet temperature is 60-80 DEG C and the screw rotating speed is 30-50 r / min. When the antidote is used for removing vomitoxin in mildewed corn, and the adding level of the effective component skeleton type SMBS is 0.1%, the using effect of the skeleton type vomitoxin antidote is optimal; when the antidote is used for removing DON (deoxynivalenol) in corn alcohol lees polluted by mycotoxin and the addition level of the effective component skeleton-type SMBS is 0.4%, the use effect of the skeleton-type vomitoxin antidote is optimal. A theoretical basis is provided for further development of the corn and the corn alcohol lees in the field of feed processing.
Owner:SOUTHWEST UNIV

Alpha-thrombin cyclic NU nucleic acid aptamer, preparation method, antidote and application

The invention relates to an alpha-thrombin cyclic NU nucleic acid aptamer, a preparation method, an antidote and application. The preparation method of the alpha-thrombin cyclic NU nucleic acid aptamer comprises the following steps: mixing and annealing an aptamer to be cyclized and a double-hairpin auxiliary chain to obtain a first mixed solution, adding T4 ligase for temperature control reaction to obtain a second mixed solution, concentrating, adding glycerol and formamide for mixing and dissolving to obtain a third mixed solution; and purifying the third mixed solution to obtain the alpha-thrombin cyclic NU nucleic acid aptamer. The invention also provides the alpha-thrombin cyclic NU nucleic acid aptamer prepared by the preparation method. The invention also provides an antidote of the alpha-thrombin cyclic NU nucleic acid aptamer. The problems that the blood half-life period is short and the thermal stability is poor due to the fact that a linear alpha-thrombin NU nucleic acid aptamer is easily hydrolyzed by nuclease are solved. According to the invention, efficient reversion of the anticoagulation effect of the alpha-thrombin cyclic NU nucleic acid aptamer is realized.
Owner:SOUTHWEST UNIV

Spermine derivatives as heparin antidotes

The invention relates to new spermine derivatives of Formula (I), wherein the meaning of the groups R1, R2, n and m is defined in the description, to a pharmaceutical composition thereof and to their use as heparin antidotes in the control of blood coagulation. The invention was developed based on the realization that it would be desirable to have improved heparin antidotes with good anticoagulant rates, based on simple, easy to produce synthetic small molecules.
Owner:CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) +1

Alpha-thrombin cyclic RE nucleic acid aptamer, preparation method, antidote and application

The invention relates to an alpha-thrombin annular RE nucleic acid aptamer, a preparation method, an antidote and application. The preparation method of the alpha-thrombin cyclic RE nucleic acid aptamer comprises the following steps: mixing and annealing an aptamer to be cyclized and a double-hairpin auxiliary chain to obtain a first mixed solution, adding T4 ligase for temperature control reaction to obtain a second mixed solution, concentrating, adding glycerol and formamide for mixing and dissolving to obtain a third mixed solution; and purifying the third mixed solution to obtain the alpha-thrombin cyclic RE nucleic acid aptamer. The invention also provides the alpha-thrombin annular RE nucleic acid aptamer prepared by the preparation method. The invention also provides an antidote of the alpha-thrombin cyclic RE nucleic acid aptamer. According to the invention, the problems of short blood half-life period and poor thermal stability caused by easy hydrolysis of a linear alpha-thrombin RE aptamer by nuclease are solved. According to the invention, efficient reversion of the anticoagulant effect of the alpha-thrombin annular RE nucleic acid aptamer is realized.
Owner:SOUTHWEST UNIV +1

Compositions and methods related to nucleic acid anticoagulants

The present disclosure provides compositions and methods related to nucleic acid molecules having therapeutic aptamers. In particular, the present disclosure provides nucleic acids molecules comprising one or more aptamers having anticoagulant activity, as well as corresponding nucleic acid antidotes, for the modulation of blood coagulation in the context of disease and surgical intervention.
Owner:NORTH CAROLINA STATE UNIV

A compound preparation for relieving selenium poisoning, feed and application thereof

ActiveCN117179147BAccessory food factorsSelenium metabolismAntidote
The present application belongs to the technical field of feed additives, and specifically provides a compound preparation for relieving selenium poisoning, which comprises taurine, vitamin E, glutathione, allicin and carotene. The compound preparation provided by the present application utilizes the synergistic effect among taurine, vitamin E, glutathione, allicin and carotene, replaces the commonly used intravenous injection of sodium thiosulfate antidote, slows down the absorption speed of selenium, relieves the oxidation of selenium to the lipid on the surface of liver cell membrane, and removes the by-products such as free radicals after selenium metabolism. By adopting sodium selenite to simulate the environment under acute high-concentration selenium exposure, it is proved that the compound preparation has certain relieving effect on the growth inhibition and liver damage caused by acute selenium poisoning.
Owner:WUHAN SUNHY BIOLOGICAL +1

DNA aptamer for treating abrus precatorius toxin poisoning and application thereof

The invention relates to a DNA (deoxyribonucleic acid) aptamer which is shown as a formula I and can be specifically combined with abrus precatorius toxin and exert inhibitory activity and application of the DNA aptamer in prevention or treatment of abrus precatorius toxin poisoning. The nucleic acid aptamer can be combined with the abrus precatorius toxin in a high-affinity and high-specificity mode, and the toxicity of the abrus precatorius toxin is effectively resisted. The invention also designs a pharmaceutical composition containing the nucleic acid aptamer sequence or the pharmaceutically acceptable salt thereof as an active ingredient, and an application of the nucleic acid aptamer sequence or the pharmaceutically acceptable salt thereof in preparation of an abrus precatorius toxin antidote drug. In addition, the nucleic acid aptamer can also be used for resisting the abrus precatorius toxin in vitro or used as a detection tool for detecting the abrus precatorius toxin in environmental and biological samples. The invention provides a new solution for first aid, treatment and detection of the abrus precatorius toxin.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

antidote peptide

The present invention relates to a detoxifying peptide, characterized in that its sequence comprises the following general amino acid sequence: N-(Val-Gly-X1-X2-Pro-Gly)n-OH, in which: N and OH correspond respectively to the N-terminal and C-terminal end of the peptide; X1 and X2 are chosen from valine (Val), glycine (Gly), threonine (Thr), asparagine (Asn), glutamine (Gln), alanine (Ala), leucine (Leu) and isoleucine (Ile); n is an integer between 1 and 3; for use in the treatment and / or prevention of a disorder associated with glycation and / or glycoxidation of proteins and / or lipids.
Owner:REGENTIS PHARMACEUTICALS

Antidote

PCT designated stage expiredWO2024256742A1Peptide/protein ingredientsProtease inhibitorsRecombinant AntithrombinAntidote
The present invention discloses a recombinant antithrombin for use in the treatment of haemorrhagic risk in a patient.
Owner:FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION DE MURCIA

Antibody for factor xa inhibitor and method for using the same

To provide an antibody for factor xa inhibitor and method for using the same.SOLUTION: One of the major limitations of anticoagulant therapy is the limitation of the ability to rapidly reverse anticoagulant activity in the case of treatment-related bleeding risk and in cases of overdosage or required emergency surgical intervention. Therefore, a specific effective antidote for all forms of anticoagulant therapy is highly desirable. The present invention relates to an antidote to an anticoagulant that targets factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives described herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.SELECTED DRAWING: None
Owner:ALEXION PHARMACEUTICALS INC